BB Biotech AG operates in the Investors sector.
In addition to historical fundamental analyses, the complete report available to purchase compares BB Biotech AG with three other
financial institutions in Europe:
IP Group Plc
of UNITED KINGDOM
sales of £234.20 million [US$320.38 million]
of which 98%
was University Partnership Business),
Blue Cap AG
(258.91 million Euros [US$303.17 million]
of which 39%
was Plastics Technology), and
Aforti Holding SA
based in POLAND
(1.01 billion Polish New Zlotys [US$256.65 million]
During the second
quarter of 2021, sales at BB Biotech AG totalled
57.65 million Swiss Francs.
This is a drop of 8.2%
from the 62.83 million Swiss Francs in sales at the company during the second quarter in 2020.
During the first two
quarters of 2021, sales totalled 86.72 million Swiss Francs, which is
than through the first two quarters of 2020.
BB Biotech AG reported sales of 280.93 million Swiss Francs (US$303.71 million)
December of 2020.
increase of 16.6%
versus 2019, when the company's sales were 240.87 million Swiss Francs.
The sales level in 2020 was fairly close to the level five years ago: in 2015, BB Biotech AG had sales
of 292.00 million Swiss Francs.